

GPR109B Antibody (N-term) Blocking Peptide Synthetic peptide Catalog # BP19262a

Specification

GPR109B Antibody (N-term) Blocking Peptide - Product Information

Primary Accession

<u>P49019</u>

GPR109B Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 8843

Other Names

Hydroxycarboxylic acid receptor 3, G-protein coupled receptor 109B, G-protein coupled receptor HM74, G-protein coupled receptor HM74B, Niacin receptor 2, Nicotinic acid receptor 2, HCAR3, GPR109B, HCA3, HM74B, NIACR2

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

GPR109B Antibody (N-term) Blocking Peptide - Protein Information

Name HCAR3

Synonyms GPR109B, HCA3, HM74B, NIACR2

Function

Receptor for 3-OH-octanoid acid mediates a negative feedback regulation of adipocyte lipolysis to counteract prolipolytic influences under conditions of physiological or pathological increases in beta- oxidation rates. Acts as a low affinity receptor for nicotinic acid. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet.

Cellular Location Cell membrane; Multi-pass membrane protein.

Tissue Location Expression largely restricted to adipose tissue and spleen.

GPR109B Antibody (N-term) Blocking Peptide - Protocols



Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

GPR109B Antibody (N-term) Blocking Peptide - Images

GPR109B Antibody (N-term) Blocking Peptide - Background

Receptor for 3-OH-octanoid acid mediates a negative feedback regulation of adipocyte lipolysis to counteract prolipolytic influences under conditions of physiological or pathological increases in beta-oxidation rates. Acts as a low affinity receptor for nicotinic acid. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet.

GPR109B Antibody (N-term) Blocking Peptide - References

Bailey, S.D., et al. Diabetes Care (2010) In press :Mandrika, I., et al. Biochem. Biophys. Res. Commun. 395(2):281-287(2010)Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)Jeninga, E.H., et al. J. Biol. Chem. 284(39):26385-26393(2009)Ahmed, K., et al. J. Biol. Chem. 284(33):21928-21933(2009)